Bristol Myers: Opdivo approved by FDA
(CercleFinance.com) - Bristol Myers Squibb announced that Opdivo (nivolumab) has been approved by the US FDA for the adjuvant treatment of adult and pediatric patients aged 12 and older with fully resected stage IIB or IIC melanoma.
Opdivo is the only de-1 inhibitor indicated for adjuvant treatment of eligible patients with stage IIB, IIC, III and completely resected stage IV melanoma1.
In the trial, Opdivo reduced the risk of recurrence, new primary melanoma or death by 58% in patients with completely resected stage IIB or IIC melanoma, compared with placebo.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Opdivo is the only de-1 inhibitor indicated for adjuvant treatment of eligible patients with stage IIB, IIC, III and completely resected stage IV melanoma1.
In the trial, Opdivo reduced the risk of recurrence, new primary melanoma or death by 58% in patients with completely resected stage IIB or IIC melanoma, compared with placebo.
Copyright (c) 2023 CercleFinance.com. All rights reserved.